Do not use in cases of hypersensitivity to the active substances or any of the excipients.
Do not use in case of hepatic dysfunction.
Do not allow rabbits, rodents (e.g. chinchillas, hamsters, and guinea pigs), horses or ruminants to access to water or feeds containing lincomycin. Ingestion by these species may result in severe gastrointestinal effects.
Do not use in laying hens.
It is sound clinical practice to base treatment on susceptibility testing of the bacteria isolated from the animal. If this is not possible, therapy should be based on local (regional, farm level) epidemiological information about susceptibility of target bacteria.
Use of the veterinary medicinal product deviating from the instructions in the datasheet (or SPC) may increase the risk of development and selection of resistant bacteria and decrease the effectiveness of treatment with macrolides due to the potential for cross-resistance.
The oral use of preparations containing lincomycin is only indicated in swine and chickens.
Do not leave access to the medicated water for other animals. Lincomycin may lead to severe gastrointestinal disturbances in other animal species.
The repeated or prolonged use should be avoided, by improving the farm management and disinfection practices.
Diagnosis should be reconsidered if improvement is not seen after 5 days.
Sick animals have a reduced appetite and an altered drinking pattern, and severely affected animals may therefore require parenteral treatment.
This powder is for use in drinking water only and should be dissolved before use.
Cases of diarrhoea or soft faeces and/or perianal region inflammation have been encountered in healthy pigs at the start of treatment. The symptoms disappeared within 5 to 8 days without interruption of the treatment. Rare cases of irritability/excitation, skin rash/pruritus were also observed. Allergic/hypersensitive reactions are rare but can occur and require stopping treatment with the veterinary medicinal product. Symptomatic treatment must be implemented.
The frequency of adverse reactions is defined using the following convention:
- very common (more than 1 in 10 animals treated displaying adverse reactions)
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).
In the event of overdose in pigs, a change in the consistency of the faeces (soft faeces and/or diarrhoea) may be observed.
In chickens treated at several times the recommended dose, enlargement of the caecum and abnormal caecum content was observed.
In case of accidental overdose, the treatment should be interrupted and restarted at the recommended dose.
Pigs: The safety of the veterinary medicinal product has not been established during pregnancy and lactation. Laboratory studies in dogs and rats have not produced any evidence of reproductive, foetotoxic or teratogenic effects for lincomycin or spectinomycin. Lincomycin is excreted in milk. Use only accordingly to benefit-risk assessment by the responsible veterinarian.
Chickens: Do not use in birds in lay.
In general, mixing with other medicines should be avoided.
The combination of lincosamides and macrolides is antagonistic, due to competitive binding to their target sites. Combination with anaesthetics may lead to possible neuromuscular blocking.
Do not administer with kaolin or pectine as they impair lincomycin absorption. If co-administration is mandatory, respect a delay of two hours between intakes.
Withdrawal period
Pigs: Meat and offal: Zero days.
Chickens: Meat and offal: 5 days.
Not for use in birds producing, or intended to produce, eggs for human consumption.
Animals must not be slaughtered for human consumption during treatment.
User warnings
People with known hypersensitivity to lincomycin, spectinomycin or soybean millfeed should avoid contact with the veterinary medicinal product. Care should be taken not to raise and inhale any dust.
Contact with skin and eyes should be avoided.
Personal protective equipment consisting of approved dust masks (either a disposable half mask respirator conforming to European Standard EN149 or a non-disposable respirator conforming to European Standard EN 140 with a filter EN 143), gloves and safety glasses should be worn when handling and mixing the product.
Wash hands and any exposed skin with soap and water immediately after use.
If symptoms such as skin rash or persistent eye irritation appear after exposure, seek medical advice immediately and show the package leaflet or label to the physician.